We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

PDGFR

PDGFR inhibitors block the platelet-derived growth factor receptors α and β (PDGFRα, PDGFRβ) of mesenchymal cells. Dimeric platelet-derived growth factor (PDGF) ligands bind the receptors, which then dimerize and autophosphorylate on tyrosine residues. PDGF signaling stimulates the growth and migration of fibroblasts, smooth muscle cells and pericytes, and it supports blood vessel maturation. Imatinib belongs to the 2-phenylaminopyrimidine class, first reported in 1995 as selective inhibitors of PDGF receptor signaling. Imatinib also inhibits the Abelson tyrosine kinase (Abl) and the stem cell factor receptor c-Kit. Sunitinib malate, axitinib and nintedanib act on PDGFR as part of broader profiles that include vascular endothelial growth factor receptors (VEGFRs). Compounds that act mainly on VEGFRs are listed in the sibling category VEGFR.

1 Item

  • CT52923
    Cat. No.
    A34875
    CAS No.
    205256-55-9

    CT52923

    CT52923 is a selective antagonist of the platelet-derived growth factor receptor (PDGFR) and acts as an ATP-competitive inhibitor. This compound demonstrates significant biological activity relevant to a range of pathological conditions, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and certain cancers. CT52923 can be utilized to explore therapeutic pathways and mechanisms involved in these diseases.

    In stock View Details
    5 mg
    $20.00
    10 mg
    $35.00
    All 5 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...